Antibiotics in the clinical pipeline at the end of 2015
- PMID: 27353164
- DOI: 10.1038/ja.2016.72
Antibiotics in the clinical pipeline at the end of 2015
Abstract
There is growing global recognition that the continued emergence of multidrug-resistant bacteria poses a serious threat to human health. Action plans released by the World Health Organization and governments of the UK and USA in particular recognize that discovering new antibiotics, particularly those with new modes of action, is one essential element required to avert future catastrophic pandemics. This review lists the 30 antibiotics and two β-lactamase/β-lactam combinations first launched since 2000, and analyzes in depth seven new antibiotics and two new β-lactam/β-lactamase inhibitor combinations launched since 2013. The development status, mode of action, spectra of activity and genesis (natural product, natural product-derived, synthetic or protein/mammalian peptide) of the 37 compounds and six β-lactamase/β-lactam combinations being evaluated in clinical trials between 2013 and 2015 are discussed. Compounds discontinued from clinical development since 2013 and new antibacterial pharmacophores are also reviewed.
Similar articles
-
Antibiotics in the clinical pipeline in 2013.J Antibiot (Tokyo). 2013 Oct;66(10):571-91. doi: 10.1038/ja.2013.86. Epub 2013 Sep 4. J Antibiot (Tokyo). 2013. PMID: 24002361 Review.
-
Antibiotics in the clinical pipeline in 2011.J Antibiot (Tokyo). 2011 Jun;64(6):413-25. doi: 10.1038/ja.2011.44. Epub 2011 May 18. J Antibiot (Tokyo). 2011. PMID: 21587262 Review.
-
Antibiotics in the clinical pipeline in October 2019.J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10. J Antibiot (Tokyo). 2020. PMID: 32152527 Free PMC article. Review.
-
[The history of the development and changes of quinolone antibacterial agents].Yakushigaku Zasshi. 2003;38(2):161-79. Yakushigaku Zasshi. 2003. PMID: 15143768 Japanese.
-
Mechanisms of resistance: useful tool to design antibacterial agents for drug - resistant bacteria.Mini Rev Med Chem. 2009 Feb;9(2):194-205. doi: 10.2174/138955709787316038. Mini Rev Med Chem. 2009. PMID: 19200024 Review.
Cited by
-
Therapeutic Efficacy of Novel Antimicrobial Peptide AA139-Nanomedicines in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia-Septicemia Model in Rats.Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00517-20. doi: 10.1128/AAC.00517-20. Print 2020 Aug 20. Antimicrob Agents Chemother. 2020. PMID: 32540976 Free PMC article.
-
Synthesis and Biological Evaluation of 3-(Pyridine-3-yl)-2-Oxazolidinone Derivatives as Antibacterial Agents.Front Chem. 2022 Jul 18;10:949813. doi: 10.3389/fchem.2022.949813. eCollection 2022. Front Chem. 2022. PMID: 35923260 Free PMC article.
-
A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii.Nat Microbiol. 2020 Sep;5(9):1134-1143. doi: 10.1038/s41564-020-0737-6. Epub 2020 Jun 8. Nat Microbiol. 2020. PMID: 32514072 Free PMC article.
-
Diamide Inhibitors of the Bacillus subtilis N-Acetylglucosaminidase LytG That Exhibit Antibacterial Activity.ACS Infect Dis. 2017 Jun 9;3(6):421-427. doi: 10.1021/acsinfecdis.7b00005. Epub 2017 May 8. ACS Infect Dis. 2017. PMID: 28448118 Free PMC article.
-
Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.ChemMedChem. 2017 Jul 20;12(14):1108-1115. doi: 10.1002/cmdc.201700170. Epub 2017 Jun 27. ChemMedChem. 2017. PMID: 28654200 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical